Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
InVivo Biosystems is a biotechnology platform/service provider for therapeutic discovery and preclinical research, with RapidGen™ as its core offering. Based on the captured content, it is closer to an “AI + whole-organism models” R&D service platform than a traditional enterprise SaaS product. It uses models such as zebrafish and C. elegans, combined with genetic tools, phenotypic analysis, RNA-Seq, and multi-omics readouts, to provide efficacy, safety, toxicity, and mechanism-of-action data for drug, nutraceutical, and biotech teams.
RapidGen™ emphasizes fast, scalable, in vivo discovery. It can evaluate 50+ variants, pathways, or therapeutic candidates in parallel, and uses AI-driven data integration to support early-stage prioritization. Its services cover high-throughput in vivo screening, acute toxicity testing in zebrafish embryos, neurotoxicity behavioral analysis, hepatotoxicity/cardiotoxicity, C. elegans lifespan and healthspan studies, mitochondrial function research, and RNA-Seq-based global gene expression analysis. Deliverables may include raw data, quality-control data, differential expression analysis, KEGG/GO pathway analysis, visualizations, and interpretive reports.
The website does not publish standard pricing. The process starts with a 30-minute discovery call, followed by a proposal with cost and timeline estimates based on the experimental scope, and then proceeds through an SOW and payment plan. Some services offer three tiers: Data Only, Data Interpretation, and Data Customization. The RNA-Seq timeline is listed as 2–3 months, while compound efficacy/safety data can be obtained in about 3 months.
The advantages are that its experimental systems capture whole-organism complexity and are closer to real biological environments than cell-based assays; zebrafish and worm models support faster cycles and higher throughput; and its 400+ customers, 600+ studies, and 10+ patents provide a degree of credibility. The drawbacks are limited information from an enterprise software perspective: there is no visible detail on permission management, security compliance certifications, APIs, self-hosting, standard integrations, or public pricing. As a project-based service, it also depends heavily on upfront communication and experimental design.
It is suitable for pharmaceutical companies, biotech firms, nutraceutical companies, academic labs, and teams that need to quickly validate candidate efficacy, safety, toxicity, and mechanisms of action. The captured text does not provide information on access from China, so this remains unknown.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on invivobiosystems.com official site.
invivobiosystems.com is an United States Health provider. TG4G tracks its product information, an overall rating of 7.0/10, and a China-accessibility score of Limited (proxy recommended). Click "Visit Official Site" to reach invivobiosystems.com directly.